Table Of contents
1. Chapter One: INTRODUCTION
2. Chapter two: Summary
3. Chapter three: Market overview
3.1. Driving factor analysis of Global biomaterial market
3.2. Defining the global biomaterial market
3.3. DEFINING The biomaterial DEVICE MARKET
3.4. Market drivers of biomaterial market
3.4.1. new and improved technologies
3.4.2. Advances in understanding of elementary biocompatibility science
3.4.3. Large application area
3.4.4. Introduction of bio-absorbable biomaterial products
3.4.5. Rising awareness
3.4.6. Development of synthetic biomaterials for medical applications
3.4.7. increase in aging population
3.4.8. Medical insurance coverage
3.4.9. Recent development in biomaterial research
3.4.10. Heightened interest in personal healthcare
3.5. Market inhibitors
3.5.1. Lack of tissue availability
3.5.2. Lack of proper reimbursement facilities
3.6. Opportunities
3.6.1. Streamlining issues in partnerships
3.6.2. Market participation by smaller companies
3.6.3. Growing need for integrated and combined materials
3.6.4. Development of new intelligent materials with dynamic molecular functions
3.6.5. Emerging preference for minimally invasive surgery
4. Chapter four: biomaterial product market
4.1. Orthopedic biomaterial market
4.1.1. Market drivers
4.1.1.1. Product penetration
4.1.1.2. Increase in demand for orthopedic biomaterial products in spine surgery
4.1.1.3. Easy surgical procedures
4.1.2. Market inhibitors
4.1.2.1. Economic constraints
4.1.2.2. Increase in competition has led to lesser profit margin
4.1.3. Opportunities
4.1.3.1. Spinal treatment expected to be on the rise
4.1.4. Top player analysis of orthopedic biomaterial market
4.1.5. Orthopedic reconstructive
4.1.5.1. Market drivers
4.1.5.1.1. Availability of a wide range of products for specific application
4.1.5.1.2. New materials with improved properties are developed to create demand
4.1.5.2. Market inhibitors and opportunities
4.1.5.3. Top Players analysis in Orthopedic Reconstructive market
4.1.5.4. Artificial hip biomaterial market
4.1.5.4.1. Cemented prostheses biomaterial market
4.1.5.4.2. Uncemented prostheses biomaterial market
4.1.5.5. Artificial knee biomaterial market
4.1.5.5.1. Non-constraint implants
4.1.5.5.2. Semi-constraint implants
4.1.5.5.3. Constraint implants
4.1.6. Trauma biomaterial product market
4.1.6.1. Market Drivers
4.1.6.1.1. Sports and other accidents are fuelling the trauma market
4.1.6.1.2. Innovation is a growth factor in trauma market
4.1.6.1.3. Plate and screw systems are driving the growth
4.1.6.2. Top Players analysis of Trauma Orthopedic biomaterial market
4.1.7. Orthobiologics
4.1.7.1. Top player analysis of orthobiologics biomaterial market
4.1.7.2. DBM
4.1.7.3. Machined bone allografts
4.1.7.4. Non proprietary allografts
4.1.7.5. Synthetic bone substitute
4.1.7.6. Bone morphogenic protein (BMP)
4.1.7.7. Platelet concentrates
4.1.8. Sports medicine
4.1.8.1. Market Drivers
4.1.8.1.1. Varying characteristics of implants suit the needs of operative sports
4.1.8.1.2. Quick healing medicines boost growth
4.1.8.2. Top player analysis of sports medicine orthopedic biomaterial market
4.1.9. Bone cement
4.1.9.1. Market Drivers
4.1.9.1.1. Lesions can be eased using bone cements
4.1.9.1.2. Bone cements can be used with antibiotics
4.1.9.2. Inhibitors and opportunities
4.1.9.3. Top player analysis of bone cement orthopedic biomaterial market
4.1.10. Spinal
4.1.10.1. Drivers
4.1.10.1.1. Spinal treatment for younger patients on the rise
4.1.10.1.2. Motion preserving devices drives growth
4.1.10.2. Inhibitors
4.1.10.3. Opportunities
4.1.10.4. Top player analysis of spine orthopedic biomaterial market
4.1.10.5. Cervical
4.1.10.6. Lumbar
4.1.11. Dental
4.1.11.1. Drivers
4.1.11.1.1. Advantages of implants over dentures and bridges
4.1.11.1.2. Implants last lifelong
4.1.11.2. Inhibitors and opportunities
4.1.11.3. Top player analysis of dental orthopedic biomaterial market
4.1.11.4. Dental bone graft and substitute
4.1.11.5. Allograft
4.1.11.6. Xenograft
4.1.11.7. Synthetic dental bone graft and substitute market
4.1.11.8. Tissue regeneration
4.1.11.9. Dental membranes
4.2. Cardiovascular
4.2.1. drivers
4.2.1.1. Advancements in treatments
4.2.1.2. Rising number of obesity cases affecting the growth of the procedures that use these products
4.2.1.3. Increase in thrombosis and heart failure treatments drive growth
4.2.1.4. Vascular surgery market is growing with the uses of biomaterials
4.2.2. Inhibitors and opportunities
4.2.3. Top player analysis of cardiovascular biomaterials market
4.2.4. Cardiac pacemakers biomaterial market
4.2.4.1. Top player analysis of cardiac pacemaker cardiovascular biomaterial market
4.2.5. Implantable Cardioverter Defibrillator
4.2.5.1. Top player analysis of implantable cardioverter defibrillator cardiovascular biomaterial market
4.2.6. Cardiac Stent
4.2.6.1. Top player analysis of cardiac stents biomaterial market
4.2.7. Artificial heart valves
4.2.7.1. Top player analysis of artificial heart valve cardiovascular biomaterial market
4.2.8. Vascular Access devices
4.2.8.1. Market Drivers
4.2.8.1.1. Demand for advanced cardiac care in developing countries
4.2.8.1.2. Eliminates repeated needle sticks
4.2.8.2. Inhibitors and opportunities
4.2.8.3. Top player analysis of vascular access devices biomaterial market
4.2.9. Peripheral vascular grafts
4.3. Wound care products
4.3.1. drivers
4.3.1.1. Multiple advantages over conventional wound care products
4.3.1.2. Supports healing process of the skin
4.3.1.3. Advanced gel based products help accelerate the healing of wounds in special category of patients
4.3.1.4. Prevention of bacterial colonization on sutures
4.3.1.5. Reduction in the cost of hospitalization
4.3.1.6. Eliminates frequent change of dressings
4.3.1.7. Increase in Diabetes foot ulcer
4.3.2. Inhibitors
4.3.3. Opportunities
4.3.3.1. Increase in penetration of negative pressure wound therapy outside the U.S.
4.3.3.2. Introduction of more efficient and cost effective therapies
4.3.3.3. Usage of natural polymer biomaterials for stability in treatment
4.3.4. Top player analysis of wound care biomaterial market
4.3.5. Internal tissue sealant
4.3.5.1. Drivers
4.3.5.1.1. Technological advances
4.3.5.1.2. Wide range of applications and features
4.3.5.1.3. Faster healing
4.3.5.2. Top player analysis of internal tissue sealant wound care biomaterial market
4.3.5.3. Fibrin Sealants
4.3.5.4. Synthetic sealants
4.3.6. Surgical Hemostats
4.3.6.1. Market Drivers
4.3.6.1.1. New surgical hemostats provide improved control of bleeding
4.3.6.1.2. Reduces the need for frequent blood transfusions
4.3.6.2. Inhibitors and opportunities
4.3.6.3. Top player analysis of surgical hemostats market
4.3.6.4. Thrombin-based hemostats
4.3.6.5. Oxidized regenerated cellulose based topical hemostats
4.3.6.6. Gelatin-based hemostats
4.3.6.7. Combination hemostats
4.3.6.8. Collagen based hemostats
4.3.6.9. Autologous based hemostats
4.3.6.10. Polysaccharide based hemostats
4.3.7. Adhesion barriers
4.3.7.1. Drivers
4.3.7.1.1. Absorbable barriers are developed for surgeries
4.3.7.1.2. Reduces adhesion probability
4.3.7.2. Inhibitors and opportunities
4.3.7.3. Top player analysis of adhesion prevention wound care biomaterial market
4.3.7.4. Films
4.3.7.5. Gels
4.3.8. Skin substitutes
4.3.9. drivers
4.3.9.1. Increased incidences of gastro-intestinal diseases
4.3.9.2. FDA approval for shifting gastrointestinal drugs from prescription drugs to over-the-counter
4.3.10. Inhibitors
4.3.10.1. Lack of awareness of probiotic cultured materials
4.3.11. Opportunities
4.3.11.1. New developments coming up in gastrointestinal wound healing
4.3.12. Top player analysis of gastrointestinal biomaterial market
4.4. Urological market
4.4.1. drivers
4.4.1.1. Availability of biodegradable materials for treatment
4.4.1.2. Development of scaffolds for the treatment of several disorders
4.4.2. Inhibitors and Opportunities
4.4.3. Top player analysis of urological biomaterial market
4.4.4. Urological stents
4.4.4.1. Market Drivers
4.4.4.1.1. Stents are used in short duration treatment
4.4.4.1.2. Broad indications and growing population boost the market
4.4.4.2. Inhibitors and Opportunities
4.4.5. Urological catheters
4.4.5.1. Drivers
4.4.5.1.1. New approach in catheter design has set performance standards to increase demand
4.4.5.1.2. Increased applicability of catheters boost the market
4.4.5.2. Inhibitors
4.4.5.3. Opportunities
4.4.5.3.1. Use of biomaterials in catheters eliminates certain disadvantages
4.4.5.3.2. Biocompatibility of chemicals can be improved in catheters
4.4.5.4. Dialysis catheter
4.4.5.4.1. Top player analysis of dialysis catheter market
4.4.5.5. Hemodialysis catheter
4.4.5.6. Peritonial catheter
4.4.5.7. Urinary catheter
4.4.5.8. Indwelling catheter
4.4.5.9. External catheter
4.4.5.10. Intermittent catheter
4.5. Plastic surgery
4.5.1. Market Drivers
4.5.1.1. More surgeons are moving towards plastic surgery market from reconstructive procedures
4.5.1.2. Cultural factors boost the market growth
4.5.1.3. Baby boomers to boost the market growth
4.5.2. Market Inhibitors
4.5.2.1. Difficulties in treating craniofacial trauma
4.5.3. Opportunities
4.5.3.1. Market has not tapped men for facial surgeries
4.5.3.2. Development of advanced procedures for quick patient recovery
4.5.4. Top player analysis of plastic surgery biomaterial market
4.5.5. Breast Implants
4.5.5.1. Drivers
4.5.5.1.1. More refined procedures are available
4.5.5.1.2. Choices available for breast implants are wider
4.5.5.2. Inhibitors
4.5.5.3. Opportunities
4.5.5.3.1. Reduction in complications will be an opportunity
4.5.5.3.2. Safety issues need to be addressed
4.5.5.4. Top player analysis of breast implants biomaterial market
4.5.5.5. Saline filled implants
4.5.5.6. Silicone filled implants
4.5.6. Injectable fillers
4.5.6.1. Drivers
4.5.6.1.1. Anti-aging has driven the market growth
4.5.6.1.2. Permanent results can be achieved using fillers
4.5.6.2. Inhibitors
4.5.6.2.1. Allergy reaction and re-absorption is a concern in injectable fillers
4.5.6.3. Opportunities
4.5.6.3.1. FDA approval not needed for fat fillers
4.5.6.4.Top player analysis of injectable fillers biomaterial market
4.5.7. Facial Implants
4.5.7.1. Drivers
4.5.7.1.1. Iraq war increased the demand for facial implants
4.5.7.1.2. Faster recovery and surgery times
4.5.7.2. Inhibitors
4.5.7.3. Opportunities
4.5.7.4. Top player analysis of facial implants biomaterial market
4.6. Other biomaterials
5. Chapter five: Biomaterial market
5.1. Ceramics
5.1.1. Drivers
5.1.1.1. Low stress shielding
5.1.1.2. No disease transmission
5.1.1.3. Material supply is unlimited
5.1.2. Inhibitors and opportunities
5.1.3. Top player analysis of ceramics market
5.1.4. Bioinert ceramics
5.1.4.1. Drivers
5.1.4.1.1. Can be used for high strength applications
5.1.4.1.2. They show high chemical stability
5.1.4.2. Inhibitors
5.1.4.3. Opportunities
5.1.4.3.1. Alumina
5.1.4.3.2. Drivers
5.1.4.3.3. Inhibitors
5.1.4.3.4. Opportunities
5.1.4.4. Zirconia ceramic
5.1.4.4.1. Drivers
5.1.4.4.2. Inhibitors
5.1.4.4.3. Opportunities
5.1.4.5. Other bioinert ceramics market
5.1.5. Bioactive ceramics
5.1.5.1. Drivers
5.1.5.1.1. They help in bone formation
5.1.5.1.2. They bond with living bone tissue
5.1.5.1.3. Inhibitors and Opportunities
5.1.5.2. Bioglass
5.1.5.2.1. Drivers
5.1.5.2.2. Inhibitors
5.1.5.2.3. Opportunities
5.1.5.3. Other bioactive ceramics market
5.1.6. Biodegradable ceramics
5.1.6.1. Drivers
5.1.6.1.1. They are the least toxic of ceramics
5.1.6.1.2. The degradable rate can be tailored
5.1.6.2. Inhibitors and opportunities
5.1.6.3. Hydroxyapetite
5.1.6.3.1. Drivers
5.1.6.3.2. Inhibitors
5.1.6.3.3. Opportunity
5.1.6.4.Others biodegradable biomaterial market
5.2. Metals
5.2.1. Drivers
5.2.1.1. Balancing act of metallic biomaterials
5.2.1.2. Improved properties of metallic biomaterials
5.2.2. Inhibitors
5.2.3. Opportunities
5.2.3.1. Improvement in corrosion resistance
5.2.3.2. Introduction of new alloys
5.2.4. Top player analysis of metallic biomaterial market
5.2.5. Pure form metals
5.2.5.1. Titanium
5.2.5.2. Gold
5.2.5.3. Silver
5.2.5.4. Platinum
5.2.6. Alloys
5.2.6.1. Drivers
5.2.6.1.1. Availability of ore for biomaterials manufacture
5.2.6.1.2. Can be sterilized easily
5.2.6.2. Inhibitors and opportunities
5.2.6.3. Top player analysis of alloy biomaterial market
5.2.6.4. High Carbon Cobalt Chromium alloy
5.3. Polymers
5.3.1. Drivers
5.3.1.1. Biodegradable naturally
5.3.1.2. Compatibility in imaging
5.3.2. Inhibitors and opportunities
5.3.3. Top player analysis of polymer biomaterial market
5.3.4. Natural polymers
5.3.4.1. Drivers
5.3.4.1.1. They are safe for use
5.3.4.1.2. They work at a molecular level
5.3.4.2. Inhibitors and opportunities
5.3.4.3. Collagen Market
5.3.4.4. Chitosan
5.3.4.5. Alginate
5.3.4.6. Others natural polymers
5.3.5. Synthetic polymers
5.3.5.1. PLA/PGA
5.3.5.2. PTFE (polytetrafluoroethylene)
5.3.5.3. Other synthetic polymers
6. Chapter Six: Application market
6.1. General surgery
6.1.1. Drivers
6.1.1.1. Suturing has become easier with the synthetic biomaterials
6.1.1.2. Stringent requirements of surgeons are met by biomaterials
6.1.1.3. Biomaterials are used as adhesion prevention materials
6.1.2. Inhibitors
6.1.3. Opportunities
6.1.3.1. The development of a permanent solution for adhesion prevention
6.1.3.2. Properties of biomaterials can be improved to increase usage
6.2. Surgical Appliances and supplies
6.2.1. Drivers
6.2.1.1. Advanced materials for surgical appliances drives growth
6.2.1.2. Surgical advances in orthopedic and prosthetic applications
6.2.1.3. Increased healthcare spending by developed countries
6.2.1.4. Tissue engineering doesn’t have any side effects
6.2.1.5. Biomaterials are used to accelerate natural phenomena
6.2.2. Market Inhibitors
6.2.2.1. Reduced availability of outside capital
6.2.2.2. Tissue engineering may require reoperation
6.2.2.3. The process of approving is slow
6.2.3. Opportunities
6.2.3.1. Demographic factors will provide growth
6.2.3.2. Increase in export opportunities
6.2.3.3. Development of artificial organs in future
6.2.3.4. Treatment of sleep disorder is under investigation
6.3. Drug delivery applications
6.3.1. Drivers
6.3.1.1. Enabling properties of biomaterials drive growth
6.3.1.2. Most of the biomaterials are bio-absorbable
6.3.1.3. Quick and effective methods have been developed
6.3.2. Inhibitors
6.3.3. Opportunities
6.4. Dental products
6.4.1. Drivers
6.4.1.1. Biomaterials have wider dental applications
6.4.1.2. Risk of dental disease is set to increase
6.4.1.3. Improvement in polymers used for dental applications
6.4.2. Inhibitors
6.4.3. Opportunities
6.5. Surgical and Medical Instruments
6.5.1. Drivers
6.5.1.1. Breakthrough in innovations of surgical instruments drive growth
6.5.1.2. Availability of cheap surgical instruments
6.5.2. Inhibitors
6.5.3. Opportunities
6.6. Electro medical equipment application
6.6.1. Drivers
6.6.1.1. There is a substantial increase in the number of patients
6.6.1.2. Demand for efficient procedures and economies of scale
6.6.2. Inhibitors
6.6.2.1. Polymers used in the equipment are prone to release toxic agents
6.6.2.2. There is a possibility of electrical leakage
6.6.3. Opportunities
6.7. Other applications
7. Chapter Seven: Geographic Analysis of biomaterial market
8. Chapter eight: Company profiles
8.1. 3DM, Inc.
8.2. AdvanSource Biomaterials Corporation
8.3. Allergan Inc.
8.4. AlloSource
8.5. Alphatec Spine, Inc.
8.6. Amedica Corporation
8.7. Angiotech Pharmaceuticals, Inc.
8.8. ApaTech Ltd.
8.9. Artimplant AB
8.10. Biocoral, Inc.
8.11. BioInteractions Ltd.
8.12. Bioretec Ltd.
8.13. Bio Syntech Canada Inc.
8.14. Boston Scientific Corporation
8.15. Collagen Matrix, Inc.
8.16. Corin Group PLC
8.17. Covalon technologies
8.18. CryoLife Inc.
8.19. Davol, Inc.
8.20. Depuy Orthopaedics Inc.
8.21. ETEX Corporation
8.22. Forticell Bioscience, Inc.
8.23. Genzyme Biosurgery
8.24. Haemacure Corporation
8.25. Inion Oy
8.26. Integra Lifesciences Holdings Corp.
8.27. International Biocomposites Ltd.
8.28. Invibio Ltd.
8.29. ISTO Technologies, Inc.
8.30. Kensey Nash Corporation
8.31. Medtronic, Inc.
8.32. Mentor Corporation
8.33. MIV Therapeutics Inc.
8.34. Olympus Terumo Biomaterials Ltd.
8.35. Organogenesis, Inc.
8.36. Orthovita
8.37. Osteotech, Inc.
8.38. Pioneer Surgical Technology
8.39. Polymer Technology Group
8.40. Protein Polymer Technologies Inc.
8.41. RTI Biologics, Inc.
8.42. Smith & Nephew plc
8.43. Stryker Corporation
8.44. Synthes, Inc.
8.45. TEI Biosciences
8.46. TORNIER Inc.
8.47. Vygon S.A
8.48. W.L. Gore & Associates Inc.
8.49. Wright Medical Group, Inc.
8.50. Zimmer Holding, Inc.
9. Chapter nine: Patent analysis
Appendix
1. U.S. biomaterial product patents
2. Europe biomaterial product patents
3. Asia biomaterial product patents
4. U.S. biomaterial patents
5. Europe biomaterial patent
6. Asia biomaterial patents
List of Tables
Summary Table Global biomaterial market, by products 2007 – 2014 ($ million)
TABLE 1 GLOBAL orthopedic BIOMATERIAL DEVICE MARKET, BY TYPES 2007 – 2014 ($ million)
TABLE 2 GLOBAL orthopedic biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 3 GLOBAL orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 4 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 5 GLOBAL reconstructive orthopedic BIOMATERIAL DEVICE MARKET, BY TYPES 2007 – 2014 ($ million)
TABLE 6 GLOBAL reconstructive orthopedic biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 7 GLOBAL reconstructive orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 8 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
TABLE 9 GLOBAL artificial hip orthopedic biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 10 GLOBAL artificial hip orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 11 GLOBAL cemented prostheses orthopedic biomaterial MARKET, BY geography2007 – 2014 ($ million)
TABLE 12 GLOBAL uncemented prostheses orthopedic biomaterial MARKET, BY geography, 2007 – 2014 ($ million)
TABLE 13 GLOBAL artificial knee orthopedic biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 14 GLOBAL artificial knee orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 15 GLOBAL non-constrainT implants orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ millions)
TABLE 16 GLOBAL semi-constrainT orthopedic biomaterials MARKET, BY geography 2007 – 2014 ($ million)
TABLE 17 GLOBAL constrainT implants orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 18 GLOBAL trauma orthopedic BIOMATERIAL DEVICE MARKET, BY TYPES 2007 – 2014 ($ million)
TABLE 19 GLOBAL trauma orthopedic biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 20 GLOBAL trauma orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 21 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 22 GLOBAL orthobiologics biomaterial MARKET, BY device 2007 – 2014 ($ million)
TABLE 23 GLOBAL orthobiologics biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 24 GLOBAL orthobiologics biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 25 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
TABLE 26 GLOBAL DBM orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 27 GLOBAL machined bone allograft orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 28 GLOBAL non proprietary allograft orthopedic MARKET, BY geography 2007 – 2014 ($ million)
TABLE 29 GLOBAL synthetic bone substitute orthopedic biomaterials MARKET, BY geography 2007 – 2014 ($ million)
TABLE 30 GLOBAL BMP orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 31 GLOBAL platelet concentrates orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 32 GLOBAL sports medicine orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 33 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 34 GLOBAL bone cement orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 35 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 36 GLOBAL spine orthopedic biomaterial MARKET, BY device 2007 – 2014 ($ million)
TABLE 37 GLOBAL spine orthopedic biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 38 GLOBAL spine orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 39 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
TABLE 40 GLOBAL cervical spine orthopedic biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 41 GLOBAL cervical spine orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 42 GLOBAL lumbar spine orthopedic biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 43 GLOBAL lumbar spine orthopedic biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 44 GLOBAL dental orthopedic BIOMATERIAL DEVICE MARKET, BY TYPES 2007 – 2014 ($ million)
TABLE 45 GLOBAL dental orthopedic biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 46 GLOBAL dental orthopedic biomaterials MARKET, BY geography 2007 – 2014 ($ million)
TABLE 47 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
TABLE 48 GLOBAL dental bone graft orthopedic biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 49 GLOBAL dental bone graft orthopedic biomaterial MARKET, BY geography, 2007 – 2014 ($ million)
TABLE 50 GLOBAL dental allograft orthopedic biomaterial MARKET, BY geography, 2007 – 2014 ($ million)
TABLE 51 GLOBAL xenograft dental biomaterial MARKET, BY geography, 2007 – 2014 ($ million)
TABLE 52 GLOBAL synthetic dental biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 53 GLOBAL tissue regeneration dental biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 54 GLOBAL dental membrane biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 55 GLOBAL cardiovascular biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 56 GLOBAL cardiovascular biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 57 GLOBAL cardiovascular biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 58 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
TABLE 59 GLOBAL cardiac pacemaker cardiovascular device MARKET, BY geography 2007 – 2014 ($ million)
TABLE 60 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 61 GLOBAL implantable cardioverter defibrillator cardiovascular biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 62 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 63 GLOBAL cardiac stents cardiovascular biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 64 GLOBAL cardiac stents cardiovascular biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 65 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 66 GLOBAL artificial heart valve cardiovascular biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 67 GLOBAL artificial heart valve cardiovascular biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 68 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
TABLE 69 GLOBAL vascular access devices cardiovascular biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 70 GLOBAL vascular access devices cardiovascular biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 71 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
TABLE 72 GLOBAL peripheral vascular grafts MARKET, BY geography 2007 – 2014 ($ million)
TABLE 73 GLOBAL wound care BIOMATERIAL DEVICE MARKET, BY TYPES 2007 – 2014 ($ million)
TABLE 74 GLOBAL wound care biomaterial MARKET, BY PRODUCTS, 2007 – 2014 ($ million)
TABLE 75 GLOBAL wound care biomaterial MARKET, BY geography2007 – 2014 ($ million)
TABLE 76 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 77 GLOBAL internal tissue sealant wound care biomaterial MARKET, BY PRODUCTS, 2007 – 2014 ($ million)
TABLE 78 GLOBAL internal tissue sealant wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 79 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 80 GLOBAL fibrin-based sealant wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 81 GLOBAL synthetic based sealant wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 82 GLOBAL surgical hemostats wound care biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 83 GLOBAL surgical hemostats wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 84 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 85 GLOBAL thrombin based hemostats wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 86 GLOBAL oxidized regenerated cellulose based hemostats wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 87 GLOBAL gelatin based hemostats wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 88 GLOBAL combination hemostats wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 89 GLOBAL collagen based hemostats wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 90 GLOBAL autologous based hemostats wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 91 GLOBAL polysaccharide based hemostats wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 92 GLOBAL adhesion barriers wound care MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 93 GLOBAL adhesion barriers wound care MARKET, BY geography 2007 – 2014 ($ million)
TABLE 94 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
TABLE 95 GLOBAL films wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 96 GLOBAL gels wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 97 GLOBAL skin substitute wound care biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 98 GLOBAL gastrointestinal biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 99 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
TABLE 100 GLOBAL urological BIOMATERIAL DEVICE MARKET, BY TYPES 2007 – 2014 ($ million)
TABLE 101 GLOBAL urological biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 102 GLOBAL urological biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 103 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
TABLE 104 GLOBAL stents urological biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 105 GLOBAL catheter urological biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 106 GLOBAL catheters urological biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 107 GLOBAL dialysis catheter urological BIOMATERIAL DEVICE MARKET, BY TYPES 2007 – 2014 ($ million)
TABLE 108 GLOBAL dialysis catheter urological biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 109 GLOBAL dialysis catheter urological biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 110 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 111 GLOBAL hemodialysis catheter urological biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 112 GLOBAL peritonial catheter urological biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 113 GLOBAL urinary catheter urological BIOMATERIAL DEVICE MARKET, BY TYPES 2007 – 2014 ($ million)
TABLE 114 GLOBAL urinary catheter urological biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 115 GLOBAL urinary catheters urological biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 116 GLOBAL indwelling catheter urological biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 117 GLOBAL plastic surgery biomaterial device MARKET, BY types 2007 – 2014 ($ million)
TABLE 118 GLOBAL plastic surgery biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 119 GLOBAL plastic surgery biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 120 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 121 GLOBAL breast implants plastic surgery BIOMATERIAL DEVICE MARKET, BY TYPES 2007 – 2014 ($ million)
TABLE 122 GLOBAL breast implants plastic surgery biomaterial MARKET, BY PRODUCTS 2007 – 2014 ($ million)
TABLE 123 GLOBAL breast implants plastic surgery biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 124 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
TABLE 125 GLOBAL saline filled implants breast implant biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 126 GLOBAL silicone gel implants breast implant biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 127 GLOBAL injectable fillers breast implant biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 128 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 129 GLOBAL facial implants plastic surgery biomaterial MARKET, BY geography 2007 – 2014 ($ million)
TABLE 130 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
TABLE 131 GLOBAL biomaterial MARKET, BY types 2007 – 2014 ($ million)
TABLE 132 GLOBAL ceramics MARKET, BY types of biomaterials 2007 – 2014 ($ million)
TABLE 133 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
Table 134 Technological advancements in ceramics market
TABLE 135 GLOBAL bioinert ceramics MARKET, BY types of biomaterials 2007 – 2014 ($ million)
TABLE 136 GLOBAL bioactive ceramics MARKET, BY types 2007 – 2014 ($ million)
TABLE 137 GLOBAL biodegradable ceramics MARKET, BY types 2007 – 2014 ($ million)
TABLE 138 GLOBAL metallic biomaterial MARKET, BY types 2007 – 2014 ($ million)
TABLE 139 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 140 GLOBAL pure form metals MARKET, BY types 2007 – 2014 ($ million)
TABLE 141 GLOBAL alloy biomaterial MARKET, BY types 2007 – 2014 ($ million)
TABLE 142 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 143 GLOBAL polymer biomaterials MARKET, BY types 2007 – 2014 ($ million)
TABLE 144 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
TABLE 145 GLOBAL natural polymer biomaterial MARKET, BY types 2007 – 2014 ($ million)
TABLE 146 GLOBAL synthetic polymer biomaterial MARKET, BY types of biomaterials 2007 – 2014 ($ million)
TABLE 147 Application market for biomaterials
TABLE 148 Global biomaterial market, by geography, 2007 – 2014 ($ million)
TABLE 149 U.S. biomaterial market, by products, 2007 – 2014($ million)
TABLE 150 European biomaterial market, by products, 2007 – 2014 ($ million)
TABLE 151 Asian biomaterial market, by products, 2007 – 2014 ($ million)
TABLE 152 3dm, inc. Product profile
TABLE 153 3dm, inc. strategy
TABLE 154 AdvanSource Biomaterials Corporation product profile
TABLE 155 allergan inc. Product profile
TABLE 156 allosource Product profile
TABLE 157 allosource strategy
TABLE 158 Alphatec Spine, Inc. Product profile
TABLE 159 Alphatec Spine, Inc. strategies and developments
TABLE 160 amedica corporation Product profile
TABLE 161 amedica corporation Developments
TABLE 162 Angiotech pharmaceuticals, Inc. Product profile
TABLE 163 Angiotech pharmaceuticals, Inc. Strategy
TABLE 164 apatech ltd. Product profile
TABLE 165 artimplant ab product profile
TABLE 166 artimplant ab strategies and developments
TABLE 167 Biointeractions Ltd. product profile
TABLE 168 bioretec ltd. product profile
TABLE 169 bio syntech canada inc. product profile
TABLE 170 bio syntech canada inc. Strategy
TABLE 171 Boston scientific CORPORATION PRODUCT profile
TABLE 172 Collagen matrix, Inc. Product profile
TABLE 173 Collagen matrix, Inc. Strategy
TABLE 174 Corin group, plc. Product profile
TABLE 175 Covalon technologies Product profile
TABLE 176 Covalon strategy
TABLE 177 CryoLife Inc, Product Profile
TABLE 178 CryoLife Inc., strategy
TABLE 179 davol, Inc. Product profile
TABLE 180 davol, Inc. Strategy
TABLE 181 DePuy Orthopedics, Inc. Product profile
TABLE 182 DePuy Orthopedics, Inc. Strategy
TABLE 183 etex corporation Product profile
TABLE 184 Etex corporation strategies and developments
TABLE 185 Genzyme Biosurgery Product profile
TABLE 186 Genzyme Biosurgery Developments
TABLE 187 nion oy Product profile
TABLE 188 ntegra Life sciences Holdings Corp. product profile
TABLE 189 ntegra Life sciences Holdings Corp. strategy
TABLE 190 International Biocomposites ltd. Product profile
TABLE 191 International Biocomposites ltd. Developments
TABLE 192 invibio ltd. Product profile
TABLE 193 invibio ltd. strategy
TABLE 194 isto technologies, inc. applications
TABLE 195 Kensey Nash corporation Product profile
TABLE 196 medtronic Inc. Product Profile
TABLE 197 Medtronic inc. strategies & developments
TABLE 198 mentor corporation Product profile
TABLE 199 MIV Therapeutics Inc. Product Profile
TABLE 200 Olympus Terumo product profile
TABLE 201 Olympus Terumo Strategy
TABLE 202 organogenesis, Inc. Product profile
TABLE 203 orthovita product profile
TABLE 204 osteotech, Inc. Product profile
TABLE 205 Pioneer Surgical Technology Product profile
TABLE 206 Pioneer Surgical Technology strategy
TABLE 207 Polymer Technology Group profile
TABLE 208 Protein polymer technologies, Inc. Product profile
TABLE 209 RTI biologics product profile
TABLE 210 RTI biologics Strategies
TABLE 211 smith & nephew plc Product profile
TABLE 212 smith & nephew plc strategy
TABLE 213 Stryker Corporation product profile
TABLE 214 Synthes inc. product profile
TABLE 215 Synthes inc. Strategy
TABLE 216 Tei biosciences Product profile
TABLE 217 tornier inc. product profile
TABLE 218 tornier inc. strategy
TABLE 219 vygon s.a Product profile
TABLE 220 vygon s.a strategy
TABLE 221 W.L. Gore & Associates Inc. Product profile
TABLE 222 Wright medical group, inc. product profile
TABLE 223 Wright medical group, inc. Developments
TABLE 224 zimmer holdings, inc. Product profile
TABLE 225 zimmer holdings, inc. strategy
List of Figures
Figure 1 Evolution of biomaterials
Figure 2 PARENTAL STRUCTURE OF biomaterials
Figure 3 Characteristics of biomaterial science
Figure 4 Factors affecting the biomaterial market
Figure 5 Global biomaterial device market, by product (2009)
Figure 6 relative potential matrix for biomaterial products market (2014)
Figure 7 Increasing Disability with age
Figure 8 Increasing World’s aging population
Figure 9 Geographical analysis of Biomaterial market (2009)
Figure 10 Biomaterials patents, by geography
Figure 11 Biomaterials patents in 2006, by geography
Figure 12 Biomaterials patents in 2008 by geography
LIST OF ACRONYMS AND ABBREVIATIONS
1. AAOS: American Academy of Orthopedic Surgery
2. AF: Atrial Fibrillation
3. BMP: Bone Morphogenic Protein
4. BTB: Bone Tendon Bone
5. CAGR: Compounded Annual Growth Rate
6. CE: Conformité Européene
7. CP: Combination Pharmacotherapy
8. CMF: Craniomaxillofacial
9. CRT: Cardiac Resynchronization Therapy
10. CSC: Cancellous Structure Ceramics
11. CT: Computed Tomography
12. DBM: Demineralized Bone Matrix
13. DES: Drug Eluting Stents
14. ESC: Environmental Stress Cracking
15. FDA: Food and Drugs Administration
16. HA: Hyaluronic Acid
17. ICD: Implantable Cardioverter Defibrillator
18. IDE: Investigational Device Exemption
19. LCP: Locking Compression Plate
20. MI: Myocardial Infraction
21. MRI: Magnetic Resonance Imaging
22. MIS: Minimally Invasive Surgery
23. MS: Multiple Sclerosis
24. OTC: Over the Counter
25. PEEK: Polyetheretherketone
26. PICC: Peripherally Inserted Central Catheter
27. PMMA: Polymethylmethacrylate
28. R&D: Research and Development
29. RF: Radio Frequency
30. ROW: Rest of the World
31. SFDA: State Food and Drugs Administration